Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06475118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

Study acronym: Myomachia
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 26, 2024 (before its estimated November 22, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jul 2025 to Nov 22, 2025
    • Study completion date: Apr 2026 to May 22, 2026
    • Start date changed from estimate of Aug 2024 to Nov 22, 2024
    • Site details revised
  2. Secondary endpoints: details revised at 2 of 4 entries
    • Study description expanded, about 2 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CHU de Reims
79 trials monitored
See 2 trials at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.
Trial Details
NCT Number NCT06475118
Lead Sponsor CHU de Reims
Conditions
(from sponsor)		 Sarcopenia, Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular, Sarcopenia
Enrollment 139 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov